Trial Profile
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Berdazimer sodium (Primary)
- Indications Genital warts
- Focus Proof of concept; Therapeutic Use
- Sponsors Novan Inc
- 01 Nov 2018 Results presented in a Novan Inc Media Release.
- 01 Nov 2018 According to Novan media release, data were published in Journal of Drugs in Dermatology.
- 20 Mar 2017 Status changed from active, no longer recruiting to completed, according to a Novan media release.